Valneva (NASDAQ:VALN) versus Cidara Therapeutics (NASDAQ:CDTX) Financial Comparison

Valneva (NASDAQ:VALNGet Rating) and Cidara Therapeutics (NASDAQ:CDTXGet Rating) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, earnings, profitability, risk and institutional ownership.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Valneva and Cidara Therapeutics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Valneva 1 1 4 0 2.50
Cidara Therapeutics 0 0 4 1 3.20

Valneva currently has a consensus target price of $36.00, indicating a potential upside of 4.74%. Cidara Therapeutics has a consensus target price of $6.45, indicating a potential upside of 747.23%. Given Cidara Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Cidara Therapeutics is more favorable than Valneva.

Valuation and Earnings

This table compares Valneva and Cidara Therapeutics’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Valneva $411.85 million 4.47 -$86.87 million N/A N/A
Cidara Therapeutics $49.57 million 1.05 -$42.47 million ($0.84) -0.91

Cidara Therapeutics has lower revenue, but higher earnings than Valneva.

Profitability

This table compares Valneva and Cidara Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Valneva N/A N/A N/A
Cidara Therapeutics -89.48% -465.76% -72.57%

Insider and Institutional Ownership

0.5% of Valneva shares are held by institutional investors. Comparatively, 46.3% of Cidara Therapeutics shares are held by institutional investors. 8.0% of Cidara Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Cidara Therapeutics beats Valneva on 6 of the 11 factors compared between the two stocks.

Valneva Company Profile (Get Rating)

Valneva SE, a specialty vaccine company, focused on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; and DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium. The company also develops VLA15, a vaccine candidate that is in Phase II clinical trial against Borrelia; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; and VLA2001, a vaccine candidate that has completed Phase I/II clinical trial against SARS-CoV-2. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. The company has collaborations with Pfizer to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. Valneva SE was incorporated in 1999 and is headquartered in Saint-Herblain, France.

Cidara Therapeutics Company Profile (Get Rating)

Cidara Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, and commercialization of novel anti-infectives. Its product pipeline includes Rezafungin and Cloudbreak. The company was founded by Kevin M. Forrest, Kevin J. Judice, and H. Shaw Warren in December 2012 and is headquartered in San Diego, CA.

Receive News & Ratings for Valneva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valneva and related companies with MarketBeat.com's FREE daily email newsletter.